Spiricort

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spiricort

Spiricort is a prescription medication that is a brand name for the active drug prednisone or, in some regional formulations, prednisolone. Prednisone is classified as a synthetic glucocorticoid, a type of adrenocortical steroid that mimics the action of cortisol, a naturally occurring hormone produced by the adrenal glands.

Quick Facts

Property Description
Active Ingredient Prednisone (or Prednisolone)
Form Oral tablet
Pharmacological Class Glucocorticoid (Corticosteroid)
Common Use Anti-inflammatory and Immunosuppressive
Status Prescription-Only (Rx)

Prednisone is primarily used for its powerful anti-inflammatory and immunosuppressive effects. It works systemically throughout the body to decrease the intensity of the inflammatory response and modify the activity of the immune system. The efficacy of glucocorticoids in controlling inflammation is well-established, as these are recognized as essential agents for managing acute inflammation.

An important differentiating pharmacological detail is that prednisone is a "prodrug." Prednisone is biologically inactive until it is converted by the liver into its active form, which is called prednisolone. This conversion is necessary for the drug to exert its primary therapeutic effects on the body's tissues and cells.

Due to its broad action, the drug has a long history of use and is indicated for managing a wide range of endocrine, rheumatic, collagen, allergic, and autoimmune disorders.

What side effects are possible with Spiricort?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential risks of Spiricort by System-Organ Class, providing a structured overview of effects across the body. The most commonly documented adverse reactions may involve fluid retention, alterations in glucose tolerance, increased appetite leading to weight gain, and changes in mood or behavior.


Safety Domains and Risks

Adverse reactions are grouped into categories such as Endocrine/Metabolic, Infectious, Psychiatric, and Musculoskeletal disorders. A key consideration is the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and Cushing's syndrome, particularly with long-term use. The risk of developing certain side effects, including decreased bone density (osteoporosis), cataracts, and glaucoma, is officially documented to increase with prolonged duration of treatment.


Serious and Population-Specific Concerns

Regulatory authorities specifically highlight a risk of serious adverse reactions, including severe allergic reactions (anaphylaxis), gastrointestinal perforation or hemorrhage, and psychiatric events such as psychosis or severe depression.

For pediatric patients, long-term, high-dose use may result in impaired growth, requiring careful monitoring. Use in pregnancy has been associated with a risk of fetal harm. Safety-related limitations stipulate that the medicine is contraindicated in patients with a systemic fungal infection and that administration of live or live attenuated vaccines is restricted while on immunosuppressive doses. Abrupt discontinuation after chronic use can lead to withdrawal symptoms and severe adrenal gland problems, underscoring the need for careful dose tapering.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that reports of acute toxicity and death following an isolated overdosage of glucocorticoids are rare, and life-threatening symptoms are generally not expected from a single event. However, any suspected overdose requires immediate medical evaluation due to the potential for severe adverse reactions.

Documented Manifestations and Serious Outcomes

Clinical manifestations of overdose are typically seen as an amplification of known corticosteroid effects, often associated with chronic high-dose exposure. These documented systemic effects may involve the central nervous system, including severe symptoms such as psychosis, hallucinations, severe depression, and convulsions (seizures). Furthermore, imbalances can occur in the cardiovascular system and fluid balance, resulting in cardiac dysrhythmias, sodium retention, and hypokalemia, which may lead to congestive heart failure in susceptible patients.

Emergency Actions and Management

Regulatory authorities mandate that emergency medical attention or the Poison Help line be contacted immediately if an overdose is suspected. This is required if the individual experiences severe, acute symptoms such as collapse, seizures, or difficulty breathing.

The official prescribing information confirms that no specific antidote is available for Spiricort overdose. Therefore, treatment is strictly supportive and symptomatic. Management typically requires continuous monitoring of the individual's vital signs and physiological parameters, with specific attention given to checking serum electrolytes and cardiac function in a supervised setting.

Therapeutic Uses of Spiricort

Spiricort is generally used to provide symptomatic support across therapeutic domains where symptoms are related to inflammatory or irritative states and create noticeable physiological strain. The medication is applied in contexts where additional symptomatic support is needed to ease the overall symptom burden.

The medication is commonly used across conditions presenting with acute episodes of respiratory symptoms (like wheezing and persistent cough), systemic discomfort (such as joint pain in autoimmune flares), and severe allergic manifestations (including extensive swelling or rash).

Quick Fact: Relief for Symptoms Related to Inflammatory States

Spiricort is relevant in contexts marked by increased discomfort or tension because it may assist with reducing the symptoms related to inflammatory states. This contributes to improved comfort and assists with maintaining functional stability during difficult episodes.

Symptomatic Support Across Key Domains

This medication plays a role in managing symptomatic relief and helps address symptom clusters that may become intense or disruptive, supporting patients during episodes of heightened discomfort. It is applied in clinical settings that involve acute or unstable symptom patterns, such as when symptoms suddenly intensify during a flare-up of a chronic condition.

Spiricort offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview on similar medications

Eligibility and Restrictions for Use

The official regulatory criteria for using Spiricort (prednisone/prednisolone) define specific groups who are eligible, restricted, or strictly prohibited from using the medicine. Populations for whom use is contraindicated include patients with systemic fungal infections or a known hypersensitivity to any component of the formulation. It is also prohibited to administer live or live attenuated vaccines when a patient is receiving immunosuppressive doses.

Eligibility Restrictions

Population Status Regulatory Rule
Pediatric Use Requires close monitoring for growth retardation; use may be not established for children under two years of age for specific indications.
Geriatric Use Use with caution due to the greater likelihood of age-related renal or hepatic function changes [Source: FDA].
Pregnancy/Lactation Infants exposed in utero must be observed for signs of adrenal insufficiency [Source: FDA]. The drug is excreted into human milk, requiring a risk-benefit assessment for use during lactation.
Comorbidity Caution Caution and monitoring are required for patients with diabetes mellitus, hypertension, congestive heart failure, active peptic ulcer, renal insufficiency, or cirrhosis of the liver [Source: EMA/SmPC]. Restricted use applies to patients with latent tuberculosis or ocular herpes simplex.

These rules establish mandatory non-eligibility for certain infection and allergy categories, while defining conditional use that requires special medical consideration concerning age, organ function, and coexisting chronic diseases.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information documents that co-administration of Spiricort (prednisone/prednisolone) with certain other substances results in specific pharmacokinetic or pharmacodynamic interaction patterns.

Documented Interaction Patterns

Interaction Type Interacting Substances and Formal Outcome
Metabolic/Exposure CYP3A4 Inhibitors (e.g., Ketoconazole) may increase the plasma concentration of the active steroid; CYP3A4 Inducers (e.g., Rifampin, Phenytoin) may decrease systemic exposure. Estrogens may also decrease metabolism, increasing the corticosteroid effect.
Pharmacodynamic Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) carry an increased risk of severe hypokalemia. Co-administration with NSAIDs is documented to increase the risk of gastrointestinal ulceration and hemorrhage.
Restrictions Mifepristone and Metyrapone are substances that are formally restricted or not recommended for co-administration. Timing rules require certain Anticholinesterase agents to be withdrawn at least 24 hours prior to initiating corticosteroid therapy in specific patients.

Co-administration with Fluoroquinolone antibiotics is associated with an increased risk of tendon rupture, which is noted to be heightened in elderly patients. The consumption of St. John's Wort may reduce the plasma concentration of the active steroid due to enzyme-inducing properties. The overall official interaction profile is structured around managing changes in systemic exposure and preventing additive pharmacological risk.

Mechanism of Action

Spiricort (Prednisolone) is a synthetic glucocorticoid that operates by modulating gene expression within cells, resulting in changes to inflammatory and immune pathways. This mechanism is initiated when the drug binds as an agonist to the intracellular Glucocorticoid Receptor ( GR), which then enters the nucleus. This complex actively represses pro-inflammatory genes (Transrepression) and activates anti-inflammatory genes (Transactivation), which modulates the cellular output of inflammatory proteins.

This genomic modulation leads to the upregulation of proteins like Lipocortin-1, which indirectly inhibits the enzyme Phospholipase A2 ( PLA2). This action prevents the synthesis of key inflammatory mediators, including prostaglandins and leukotrienes, which results in altered local vasodilation and fluid dynamics. Furthermore, the drug alters the chemical environment and reduces the expression of adhesion molecules, suppressing the proliferation, survival, and movement of immune cells, such as T-lymphocytes and monocytes. This action reduces the accumulation of responsive cells at sites of physiological activity, which contributes to the modulation of immune responsiveness.

Dosage and Administration Information

Spiricort, containing the active ingredient prednisone, is administered solely via the oral route through its approved forms, including immediate-release tablets, delayed-release tablets, and oral solutions.

Administration Scope

The initial daily dose for adults typically ranges from 5 mg to 60 mg, depending on the therapeutic requirement. Treatment is guided by a dose reduction strategy, where the initial amount is gradually lowered to the lowest maintenance dose that sustains the desired response. The medication is commonly taken as a single dose each morning, a pattern used to align with the body's natural cortisol production cycle. Alternatively, the dose may be divided throughout the day or administered via Alternate Day Therapy (ADT) for long-term regimens.

Procedural Instructions

Immediate-release forms of the tablet should be consumed with food or milk to comply with administration guidance. Certain specialized forms, such as delayed-release tablets, must be swallowed whole and are not designed to be crushed or split. For liquid solutions, a marked measuring device is necessary for accurate dosing.

When treatment is concluded, the dose must be gradually tapered and never halted abruptly, particularly after prolonged use. For pediatric use, dosing is based on body weight or body surface area. Protocol also instructs that dosage may require a temporary adjustment during periods of major physical stress, such as surgery or trauma.

Recent Clinical Evidence

Research evidence / Overview of studies for Spiricort (Prednisone/Prednisolone)


Evidence for Use in Rheumatic and Autoimmune Conditions

The research base for Spiricort in chronic conditions like Rheumatoid Arthritis (RA) and Polymyalgia Rheumatica (PMR) includes a significant number of studies. Studies used in research exploring how symptoms change over time include both Randomized Controlled Trials (RCTs) and long-term observational studies. For RA, research examined outcomes related to physical discomfort and functional imbalance, as well as the presence of radiographic damage to the joints. Findings from observational settings described patterns where inflammation markers were lower and radiographic damage measurements remained stable in some long-term cohorts where low doses of the drug were used alongside other treatments for RA. For PMR, studies reporting how symptoms evolved in the observed populations, particularly noting changes in stiffness in the short term, contribute to the broader evidence landscape.

Evidence for Acute and Short-Term Inflammatory Episodes

Spiricort was studied for managing conditions associated with acute or disruptive episodes, such as acute lower respiratory tract infections in hospitalized adults. The research for these uses primarily relies on short-term Randomized Controlled Trials (RCTs) and systematic reviews. Research examined outcomes describing episodic or acute changes, such as the average length of hospital stay and the need for mechanical ventilation in pneumonia studies. Studies have also explored short-term support in joint conditions like Knee Osteoarthritis (OA), tracking patient-reported outcomes describing perceived discomfort. Evidence for use in patients with less severe forms of pneumonia remains mixed and heterogeneous across multiple meta-analyses.

Limitations and Gaps in the Current Research

The evidence highlights what is known — and what is still uncertain — about the use of Spiricort. A key research limitation is that follow-up durations were limited in many short-term RCTs, meaning the certainty remains low regarding the full range of long-term outcomes. Data for long-term structural outcomes (such as cartilage loss) following systemic oral use for Knee OA are not fully established. Comparative evidence is lacking in some areas, and evidence quality varies across studies, leading to a need for continued, high-quality research to address these knowledge gaps.

Key Studies & References

  1. Corticosteroid therapy for nephrotic syndrome in children (Cochrane Review)

Frequently Asked Questions (FAQ)

Common questions about Spiricort (FAQ)


Q: Can I take Spiricort with over-the-counter pain relievers?

Official regulatory documents indicate that taking Spiricort alongside certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is associated with an increased risk of gastrointestinal issues. However, a common over-the-counter pain reliever like acetaminophen is generally not known to cause this type of interaction.


Q: Is Spiricort safe to use long-term?

Official information describes that continuous, long-term use of corticosteroids is associated with potential risks, including decreased bone density, cataracts, glaucoma, and suppression of the HPA axis. Official guidelines describe that monitoring is necessary for patients taking the medicine for an extended period.


Q: Can children or teenagers take Spiricort?

The use of Spiricort in children and teenagers is subject to official parameters, with dosing determined by body weight or body surface area. Long-term, high-dose use may result in impaired growth, and official documents note that close medical monitoring is required.


Q: Can elderly people use Spiricort?

Spiricort may be used by the elderly, but official guidelines note that caution and monitoring are necessary due to the higher likelihood of age-related changes in liver or kidney function. Regulatory documents also note an increased risk of tendon rupture when the medicine is used concurrently with certain fluoroquinolone antibiotics in this population.


Q: Is Spiricort safe to use during pregnancy?

Regulatory documents indicate that use during the first trimester has been associated with a potential risk of fetal harm. Official guidelines describe that infants exposed in utero require monitoring after birth for potential signs of adrenal insufficiency.


Q: Is it necessary to take Spiricort at the exact same time every day?

The medicine is often taken as a single dose in the morning, a pattern designed to align with the body’s natural production cycle of the cortisol hormone. Following a consistent routine can help reduce certain side effects, such as trouble sleeping.


Q: What does 'contraindication' mean in relation to Spiricort?

A contraindication is a strict regulatory rule that identifies specific medical conditions or situations where a drug is not authorized for use by regulatory bodies because the risk of harm outweighs any potential benefit. For Spiricort, having a systemic fungal infection is listed as a contraindication.


Q: How quickly does Spiricort usually start working?

Spiricort (prednisone) is classified as a prodrug, meaning it must first be converted by the liver into its active form (prednisolone) to take effect. Pharmacokinetic studies describe the active form as having a half-life of approximately three to four hours in adults.


Q: If I miss a dose of Spiricort, what happens?

Official patient information states that the instruction for a missed dose is to take it as soon as it is remembered. The guidance specifies that only a single dose is to be taken within a 24-hour period to avoid exceeding the recommended daily amount.


Q: Is it normal to feel tired when first starting Spiricort?

The drug's official adverse reaction profile includes reports of general discomfort and fatigue. Regulatory information also notes that unusual weakness or fatigue may be a sign of adrenal gland function changes, which are monitored by healthcare providers.


Q: Are there any food or drinks I need to avoid while on Spiricort?

While specific foods are generally not restricted, official regulatory documents caution that the herbal supplement St. John’s Wort may reduce the concentration of the active steroid in the blood.


Q: How long does the effect of a single dose of Spiricort last?

The drug is typically eliminated from the body within about 22 hours after a dose. Its anti-inflammatory effect is considered intermediate-acting, with a biological half-life generally ranging between 12 and 36 hours.


Q: Does alcohol change the way Spiricort works in the body?

The official product label does not specifically detail a pharmacokinetic interaction with alcohol. However, general patient safety guidelines often include cautions about minimizing alcohol intake when taking medicines that can affect the gastrointestinal system.


Q: Is Spiricort the same as a biologic medicine?

No, Spiricort is not a biologic medicine. It is a chemical-based synthetic glucocorticoid, meaning it is manufactured in a lab. Biologic medicines are derived from living organisms, are much larger, and generally work by targeting specific immune pathways.


Q: Does Spiricort affect sleep patterns?

Official documents list insomnia, or trouble sleeping, as a potential common side effect of Spiricort. This may occur because the medicine can act as a stimulant, potentially affecting behavioral or mood patterns.


Q: Does Spiricort have a maximum duration of use recommended in official guidelines?

Official prescribing guidance does not set a single maximum duration of use. Instead, it states the prescribing principle is to use the lowest effective dose for the shortest duration necessary to control symptoms.


Q: Are there specific laboratory tests recommended while on Spiricort?

Official regulatory documents describe the necessity of monitoring certain lab tests for patients receiving long-term treatment. These can include checking blood pressure, sodium and potassium serum levels, and bone density.


Q: Does Spiricort carry a Black Box Warning in the US?

The official FDA Prescribing Information for Spiricort does not display a Boxed Warning (often referred to as a Black Box Warning). However, it does include extensive warnings about potential serious risks in the Warnings and Precautions section of the label.


How should Spiricort be stored and disposed of?

The storage and disposal instructions for Spiricort (prednisone/prednisolone tablets) are strictly governed by official regulatory requirements to ensure product stability and safety.

Storage Requirements

Labeled Storage Requirement Official Regulatory Statement
Temperature Store at Controlled Room Temperature between 20 C and 25 C (68 F and 77 F). Excursions up to 30 C (86 F) are permitted; avoid excessive heat.
Protection Keep the container tightly closed and in the original package to protect from moisture and light.
Child Safety The product must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Spiricort must be disposed of in accordance with all applicable local regulations for pharmaceutical waste. The official instruction is to not dispose of the medication via wastewater unless specifically directed to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spiricort found in:

A-Z Index: